1- BSc student, Department of Medical Immunology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran 2- .BSc student, Department of Medical Immunology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran 3- . BSc student, Department of Medical Immunology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran 4- Assistant Professor, Student Research Committee, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran & Department of Medical Immunology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran 5- Associate Professor, Gastroenterology and Hepatology Research Center, Kerman University of Medical Sciences, Kerman, Iran & Department of Medical Immunology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran 6- Assistant Professor, Student Research Committee, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran & Department of Medical Immunology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran , fsedghy@gmail.com
Abstract: (411 Views)
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a major advance in immunotherapy, with remarkable efficacy in hematologic malignancies. However, translating this success to solid tumors is associated with several challenges, including antigen heterogeneity, an immunosuppressive tumor microenvironment, insufficient T-cell infiltration, and systemic toxicity. In addition, the complex and costly manufacturing process of CAR-T cells remains a major barrier to the broader implementation of this approach. This review summarizes CAR structure and generation, key steps in CAR-T cell manufacturing, target antigens, biological and engineering challenges, emerging strategies to overcome current limitations, toxicity management, and approved CAR-T–based products. Overall, this review highlights the principal barriers to CAR-T implementation and outlines strategies that may improve its safety, efficacy, and translational potential, particularly in solid tumors.
Nezhadravari M, Shamsedini E, Amooei A, Zahedi M, Mahmoodi M, Nosratabadi R et al . CAR T Cell Therapy: Biological Foundations, Clinical Applications, and Emerging Challenges. , SJKU. 2026; 31 (5) URL: http://sjku.muk.ac.ir/article-1-9163-en.html